Aim: Portal vein thrombosis (PVT) is one of the most critical disorders in liver disease patients. These patients have the imbalance of coagulation and coagulation inhibition resulting from decreased levels of coagulation inhibitory factors, such as protein C, protein S, and antithrombin III (AT-III). We designed this randomized, double-blind, placebo-controlled trial comparing the safety and efficacy of AT-III for PVT in liver disease patients with those who received no treatment.
INTRODUCTION

P
ORTAL VEIN THROMBOSIS (PVT) is not a rare complication in patients with cirrhosis, and the incidence at 1 year has been reported to be 7.4% and 11% in two cohort studies. [1] [2] [3] Portal vein thrombosis may worsen liver function, esophageal varices, and ascites, 4 and may increase the risk of death after liver transplantation; 5 therefore, PVT is one of the most critical conditions in patients with liver disease and must be remedied as soon as possible.
Interventional radiological treatment is an effective therapy for severe PVT; however, this procedure, especially that using the transjugular intrahepatic portosystemic shunt, has been controversial because it requires an invasive approach by a skilled surgeon. 6, 7 Anticoagulation therapy could be a less invasive option in patients with PVT because patients with advanced cirrhosis have the imbalance of coagulation and coagulation inhibition that results from low platelet counts and decreased levels of coagulation inhibitory factors, such as protein C, protein S, and antithrombin III (AT-III). 6, 8 Previous studies have reported that anticoagulation treatment with low-molecular-weight heparin (LMWH) or vitamin K antagonists (VKAs) may be associated with recanalization 2,3,9,10 and prophylaxis 11 of PVT. However, the role of anticoagulation in treating PVT in cirrhosis patients remains controversial. 12 Patients with liver disease may experience bleeding complications as well as thrombotic episodes. 13 Thrombotic events in cirrhosis patients cannot be explained by a reduction in both pro-and anticoagulants, and cirrhosis patients may be in hemostatic balance as a result of concomitant changes in both pro-and antihemostatic pathways. 14 Kawanaka et al. 15 reported in their prospective study that a lower concentration of AT-III activity was significantly associated with PVT in patients with cirrhosis after splenectomy, and treatment with AT-III is likely to prevent PVT from developing. Furthermore, Imai et al. 16 reported that they resolved PVT after treatment with AT-III in a patient who was a candidate for a liver transplant.
Based on these reports and the possible anticoagulation activity of AT-III without the risk of bleeding, we designed this randomized, double-blind, placebo-controlled trial comparing the safety and efficacy of AT-III at the primary end-point of patients who obtained complete or partial recanalization of PVT and the proportion of such patients.
METHODS
Study design and procedures
T HIS RANDOMIZED, DOUBLE-BLIND, placebocontrolled study was carried out at 55 hospitals in Japan (Document S1). From October 2014 through to March 2016, a total of 104 patients provided written informed consent to participate in this study. Patients with PVT (20 years old or older) who matched the following inclusion criteria were consecutively enrolled: PVT that occupied more than 50% of the cross-sectional lumen of the main portal vein, portal vein branches, superior mesenteric vein, or the splenic vein and the absence of thrombosis during the previous 6-month period on imaging diagnosis (computed tomography [CT] , color Doppler ultrasonography [US], or magnetic resonance imaging), or thrombosis progression that was more than 50% increase in the thrombus in the lumen compared with the imaging in the previous 6 months. Decreased serum level of AT-III (≤70%) at the diagnosis of PVT was another inclusion criterion.
Patients were excluded if they had: (i) a tumor thrombus in the portal vein; (ii) ongoing hepatic intra-arterial chemotherapy such as with an implantable reservoir system; (iii) hepatocellular carcinoma of more than 3 cm in diameter or four or more hepatocellular carcinomas; or (iv) anticoagulation therapy (i.v. or s.c.) or hemostasis with an enzymatic hemostatic agent in the 7-day period before written informed consent was obtained. To ensure safety, patients were also excluded if they had: (v) a Child-Pugh score of 11 or higher; (vi) hemorrhage; (vii) history of shock or hypersensitivity to AT-III; (viii) history of allergy to iodine and/or X-ray contrast medium, complication of serious thyroid disease, or reduced renal function; or (ix) if they were pregnant or nursing infants.
The onsite investigators diagnosed a main cause of PVT in a subjective manner (cirrhosis, portal hypertension, prior intervention, gastroesophageal varix, and HCC). A diagnosis of portal venous tumor invasion was established in all patients by CT on the basis of the following criteria: (i) a low-attenuation intraluminal filling defect with expanded macroscopic hepatic vascular invasion adjacent to the primary tumor during the portal phase; and (ii) an enhanced inner side of the filling defect during the arterial phase.
The patients were centrally registered and randomly assigned to either the AT-III group or the placebo group after stratification. The criteria used to ensure intergroup balance by dynamic assignment were patient AT-III activity in the screening phase and having undergone a splenectomy. The randomization code was computer-generated by independent staff members and not broken until the completion of the study. The treatment assignments were contained in opaque, sealed envelopes.
The AT-III (1500 U/day) and placebo preparations used in this study were manufactured by Nihon Pharmaceutical Co., Ltd. (Tokyo, Japan). Because the placebo preparation was composed of physiological saline, the appearance of the AT-III preparation and the placebo preparation after dissolution could be differentiated. Therefore, the independent staff members at each study institution separately prepared the solutions, and other independent staff members administered the dosing solutions and evaluated the efficacy and safety in each patient to maintain blinding. The bottles of the preparation were masked when prepared by the independent staff members in charge of preparation and were provided to the staff members in charge of administration.
The patients received an i.v. drip infusion of their assigned preparation for 5 consecutive days (days 1-5). The study drug could be additionally given up to a total of three times in a 5-day consecutive infusion if the thrombus appeared to be decreasing in size. Doppler US examinations were carried out at the following time points: throughout the first dose (days 2-4), post-first dose, or post-additional dose. Color Doppler US was carried out with low-frequency curve transducers (3.5-5 MHz) to allow greater penetration of the US beam. The gain and color filter were adjusted to allow adequate color-flow mapping. For the flow and PVT evaluation, major and minor axis dimensions with/without color Doppler US were viewed and recorded. The onsite investigators evaluated US changes of the thrombi by grading the response to the preparations in a subjective manner (complete response, 0%; partial response, ≤50%; slight response, 51-75%; no response, 76-100%; progression, ≥101%, compared to before treatment) by reference to the US image. The continuation of treatment with the study drugs was decided according to the grade of the response after the initial 5-day course (Fig. 1) . The onsite investigators evaluated adverse events (AEs) and adverse drug reactions (ADRs) by the laboratory data, clinical symptoms, and physical findings after application of the assigned drug.
Contrast enhanced CT (CECT) was carried out before and after the initial 5-day course for every patient. The patients who received an additional 5-day course had another CECT after their final treatment course. The CT equipment used in this study was limited to a multidetector CT scanner, with 64 (or more) detector rows that yielded a slice thickness of 1.25 mm, and the recommended conditions of CECT were: 120 kV, 120 mAs, 0.5 s/rot (scan speed), 240-350 mgI/mL (contrast medium) at a rate of 3.0 mL/s followed by a bolus of 30 mL physiological saline solution. A technician, independent from the onsite institution, reconstructed all CT raw data with the slice thickness of 1.25 mm. Response to the assigned drugs on CECT was evaluated by a radiologist who worked independently from the onsite institution and was blinded to the treatment. Similar to the Luca et al. 17 report, the radiological assessment of the PVT was defined as complete response (0%), partial response (≤50%), slight response (51%-75%), no response (76%-100%), and progression (≥101%) when compared with before treatment. A reader independently measured the PVT measurements using dedicated software featuring semi-automatic segmentation with linear interpolation, Figure 1 Schematic diagram of the treatment procedure for portal vein thrombosis in patients with liver disease. The study drug antithrombin III, or placebo, was given for 5 consecutive days. The continuation of the study drug was decided according to the evaluation of portal vein thrombosis using ultrasound (US) imaging. CR, complete response; CT, computed tomography; NR, no response; PR, partial response; SR, slight response. allowing manual adjustments, if necessary (Myrian; Intrasense, Paris, France). Region growing for blood vessel segmentation was carried out using the automatic seed selection method based on spectrum information that can ensure the stability of region growing, while significantly reducing manual intervention. A third party (Micron Technology, Tokyo, Japan) found and selected radiologists considering expertise, experience, no conflicts of interest, and not having any financial interests among the radiologists and sponsor/the third party.
All laboratory test analyses of blood and urine were undertaken at an institute independent from the onsite institutes. Antithrombin III and thrombin-antithrombin complex were not disclosed to the onsite investigators until the completion of the study.
This study was approved by the institutional review boards of each participating center and was carried out in accordance with the Good Clinical Practice guidelines and the ethical principles of the Declaration of Helsinki. This study is registered at ClinicalTrials.gov, identifier NCT02250391. This study was funded and the data analyses were assisted by Nihon Pharmaceutical Co., Ltd.; and the authors had full access to the relevant data, and reviewed and approved the final manuscript.
Outcomes
The primary outcome was the proportion of patients with complete response or partial response as evaluated in a cross-sectional area of the PVT on CECT images by an independent radiologist. As a secondary outcome, the changes in the CT measurements of a cross-sectional area, volume, and length of the PVT, and the number of patients in the radiological assessment, were assessed before and after treatment in both groups.
Incidence of ADRs was compared between the AT-III group and the placebo group.
Sample size and statistical analyses
Analyzes were carried out on the full analysis set which included all randomized patients who received the study drugs at least once. Missing CT data on the post-final dose were input by the post-first dose (the last observation carried forward method). The target number of 35 patients per group was calculated on the basis of the results of our previous data (unpublished) and several previous reports. 2, [9] [10] [11] 17, 18 Those investigators reported that the efficacy of anticoagulation in treating PVT was 70-80% 2,9-11 and spontaneous regression of PVT was 30-40%. 17, 18 We assumed the proportion of patients who achieved complete or partial response was 75.0% in the AT-III group and 33.3% in the placebo group. The target sample size required to detect a difference in primary outcomes between the groups with a significance level of 5% and a power of 90% was calculated to be 35 per group by Fisher's exact test. Efficacy analyses included data from all randomized patients treated with the assigned drugs. The primary outcome was analyzed by Fisher's exact test at a two-tailed significance level of 5%. An adjusted logistic regression model was conducted including baseline variables that were potential univariate predictors of primary outcome (with a conservative univariate P-value set at 0.15). The secondary outcome of the CT measurements were calculated using ANCOVA on the post-dose values to assess the group differences with P-values, mean difference, and standard error. Baseline values were included as covariates. The number of patients in the radiological assessment of the PVT was analyzed using the Wilcoxon rank-sum test with a two-tailed significance level of 5%. For the incidences of AE and ADR, a 95% confidence interval (CI) was calculated for each group, and Fisher's exact test was used to compare the groups. All analyses were carried out with the statistical software package SAS, release 9.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Study cohort
F ROM OCTOBER 2014 through to March 2016, a total of 104 patients provided written informed consent to participate in this study. Thirty-one patients were not enrolled in the study because they did not meet the inclusion criteria or because they met the exclusion criteria (AT-III <70%, 18 patients; 6 months or more before diagnosis of the PVT or <50% in the lumen of the main portal vein, 8 patients; poor imaging of US, 4 patients; hepatocellular carcinoma more than 3 cm in diameter, 1 patient). The remaining 73 patients were assigned the drugs according to the study protocol. Thirty-six patients were randomly assigned to the AT-III group and 37 patients to the placebo group. One patient did not receive treatment because the patient was expected to later meet the exclusion criteria. The allocation of the patients to the study groups and reasons for exclusion are shown in Figure 2 .
The demographic and other baseline characteristics of the two groups are shown in Tables 1 and 2 . There were 70 patients (97.2%) with cirrhosis, the remaining 2 patients (2.8%) with idiopathic portal hypertension or cholangiocarcinoma, and all patients were Japanese. There were 51 patients (70.8%) with newly formed PVT, and 21 patients (29.2%) with thrombosis progression compared to the imaging within the previous 6 months.
Significant differences between the AT-III and placebo groups were seen in age, body weight, possible causes of PVT (Table 1) , and thrombus occupancy in the lumen ( Table 2 ). The other characteristics of the two groups were well matched (Tables 1 and 2 ). Seventeen patients in the AT-III (47.2%) and 12 patients in the placebo group (33.3%) continued with additional courses of therapy (two times in the 5-day consecutive infusion of the study drug: 5 patients in the AT-III group and 2 patients in the placebo group; and three times in the 5-day consecutive infusion: 12 patients in the AT-III group and 10 patients in the placebo group). Prior interventions (hepatectomy, endoscopic variceal ligation, balloon occulted retrograde transvenous obliteration, partial splenic embolization, transarterial embolization, and radio frequency ablation) were the cause of PVT in 9 patients in the AT-III group (25.0%) and 2 patients in the placebo group (5.6%).
Primary outcome
The proportion of patients with complete response or partial response of the PVT was significantly higher in the AT-III group (55.6%; 20/36 patients; 95% CI, 38. Figure 3 shows that the thrombi had gotten smaller in the AT-III group. Maximum thrombus occupancy in the lumen was used for the analyses. The CT measurements of the PVT (cross-sectional area, volume, and length) are listed in Table S1 .
Secondary outcomes
The distributions of CT measurements (cross-sectional area, volume, and length) were calculated for pre-dose, post-first dose, and post-final dose, adding all the time points after the additional doses. When the mean differences of the cross-sectional areas in the pre-and postfirst doses, or the pre-and post-final doses were compared between the groups, the AT-III group showed a greater decrease (P = 0.021 and P = 0.001, respectively). In measurements of volume, the mean differences in the pre-and post-final doses in the AT-III group were significantly lower than those in the placebo group (P = 0.049), although the value in the pre-and post-first doses did not differ significantly between the groups (P = 0.058). Regarding length, the mean differences in pre-and post-first doses in the AT-III group were significantly lower than those in the placebo group (P = 0.023), but the difference in pre-and post-final doses did not differ significantly between the groups (P = 0.219) ( Table 3) .
The numbers of patients in the radiological assessment of the PVT calculated for post-first and post-final doses are shown in Table 4 . Compared with the placebo group, the AT-III group had higher proportions of patients with more effective responses at both time points (P = 0.003, post-first dose; P < .001, post-final dose; Wilcoxon rank- Values show as mean (range) unless otherwise noted. †n = 34 in the AT-III group, 2 patients with idiopathic portal hypertension or cholangiocarcinoma.
"Other" includes, in the AT-III group, 1 patient with non-alcoholic steatohepatitis, 2 patients unknown; in the placebo group, 3 patients with non-alcoholic steatohepatitis, 4 patients unknown.
-, not analyzed; AIH, autoimmune hepatitis; F, female; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; M, male; PBC, primary biliary cholangitis.
sum test). The number of patients in the Doppler US assessment of the PVT calculated for days 2-4, post-first, and post-final doses are shown in Table S2 .
Safety findings and laboratory assessments
The overall incidences of AEs and ADRs did not differ significantly between the two groups (P = 0.312, 1.000, Fisher's exact test, respectively) and are shown in Table  S3 . Serious adverse events (SAEs) that occurred in this study were: bacteremia (1 patient), recurrent hepatocellular carcinoma (2 patients), venous thrombosis limb (1 patient), and advanced cirrhosis (1 patient) in the AT-III group; and gastrointestinal hemorrhage (1 patient), abrupt progression of PVT (1 patient), and pyrexia (1 patient) in the placebo group. All serious adverse events required prolongation of hospitalization for treatment, but that was thought to be unrelated to the assigned drugs. PVT occurrence assessed by imaging diagnosis in previous 6 months prior to enrollment. Data are shown as n (%); measurements are expressed as median (minimum-maximum). Laboratory assessments of the functional coagulative data are shown in Figures, S1-S4 . In the AT-III group, the levels of AT-III activity had significantly increased over a period of the study. In the values of fibrin/fibrinogen degradation products, D-dimer, and thrombin-antithrombin complex, the mean differences in the pre-and post-final doses in the AT-III group were significantly lower than those in the placebo group.
DISCUSSION
T O OUR KNOWLEDGE, this is the first randomized, double-blind, controlled trial to assess the safety and efficacy of AT-III in patients with PVT, compared with patients with PVT who did not receive any treatment. We showed that the proportion of patients with complete response or partial response of the PVT was significantly higher in the AT-III group (55.6%; 20/36 patients) than in the placebo group (19.4%; 7/36 patients), although AEs and ADRs did not differ significantly between the two groups. Therefore, we propose that AT-III should be one of the essential therapies for patients with PVT in cases of lower concentration levels of AT-III.
At present, standard treatments for PVT have not been established in patients with cirrhosis; although various treatments, such as pharmacotherapy, 10, 11, 19 interventional therapy, 6 and surgery, 20 are undertaken all over the world. The rate of portal vein recanalization ranges from 70% to 80% in cirrhotic patients with PVT after anticoagulation therapy. 2, [9] [10] [11] [17] [18] [19] In preventing PVT, Villa et al.
11 undertook a randomized controlled trial in patients with advanced cirrhosis. They showed that enoxaparin completely prevented PVT for 2 years and improved survival without relevant side-effects or hemorrhagic events. However, platelet counts significantly decreased in enoxaparin-treated patients during treatment. Heparin-induced thrombocytopenia is a lifethreatening complication of exposure to heparin that occurs in up to 5% of patients exposed, regardless of the dose, schedule, or route of administration. 21 The Baveno VI Consensus Workshop reported that patients with low platelet counts (e.g., <50 × 10 9 /L) are at higher risk of both PVT and bleeding complications under anticoagulation and require more caution. 22 Therefore, the risk-benefit ratio of anticoagulation therapy in cirrhotic patients with PVT has to be carefully assessed. The most important advantages of AT-III over anticoagulants are expected to include fewer AEs and an extremely low likelihood of serious life-threatening complications, especially bleeding. Vitamin K antagonists inhibit coagulation factors II, VII, IX, and X. Heparin and LMWH can greatly increase AT-III activity and inhibit coagulation factors IIa and Xa. Low levels of AT-III activity in patients with PVT are considered factors affecting the risk of bleeding and the reduction rate of PVT when heparin or LMWH is used. The medical cost of AT-III concentrates (1500 U/ day, 5 days:~$32 250 in the USA) may be higher than that of LMWH (4000 U/day, 48 weeks:~$2744 in the USA), although the optimal duration of anticoagulation therapy with LMWH has not been determined. However, safer treatment is required, especially in patients with advanced cirrhosis who may have life-threatening bleeding events, as the medical cost markedly increases once a life-threatening event occurs. Therefore, the use of AT-III concentrates has a significant advantage during anticoagulation treatment because AT-III itself is a physiological anticoagulation factor. 15 It is noteworthy that 19.4% of patients in the placebo group had complete response or partial response. We assumed by referencing some retrospective studies that the efficacy rates of the primary outcome were 75.0% in the AT-III group and 33.3% in the placebo group as point estimates. The primary outcome was 15-20% lower than the estimates in both groups, although the group difference of the primary outcome was confirmed in this study. To minimize bias, we adopted an accurate and objective method for efficacy assessment for PVT using CECT by an independent evaluation. Therefore, this outcome may be a strict measure of effectiveness compared with other retrospective studies. In this study, enrolled patients had newly formed PVT or thrombosis progression compared with their previous 6-month imaging diagnoses. The background factors may affect the efficacy rates compared to other retrospective studies. Furthermore, significant differences between the AT-III and placebo groups were seen in background factors, especially possible causes of PVT: there might be no difference between "cirrhosis" and "portal hypertension" due to subjective evaluation by onsite investigators. The undefined evaluation of the background factor might be a potential bias between the AT-III and placebo groups, although the primary outcome did not change the association after adjusting for the baseline variables, and the efficacy rates of patients with PVT caused by prior intervention were 55.6% (5/9 patients) in the AT-III group and 0% (0/2 patients) in the placebo group. There was no significant difference between the AT-III and placebo groups in the other background factors such as Child's grade, platelet count, and coagulation inhibitory factors (Table 1) .
Doppler US examinations were carried out to decide the additional doses of the study drugs because the CECT examination was limited by consideration of the radiation exposures from the CT scans once a week. Doppler US is the imaging technique frequently used to diagnose PVT. However, the assessments in the present study were subjective and based on unestablished criteria, although they were defined in accordance with the radiological assessments.
A limitation of the present study was that a minimum of 6 to a maximum of 27 days was allowed to show the efficacy of this treatment. Because the recurrence of PVT is another problem in patients with PVT, anticoagulation is certainly essential to maintain the recanalization in patients with complete response or partial response. 10 Furthermore, 55.6% of the patients in the AT-III group had lower recanalization than patients in previous studies who were receiving other medications. Also warranted are studies evaluating AT-III in combination with heparin, LMWH, and VKAs as a bridge to these anticoagulants. Another limitation was the short follow-up period of 16 (±3) days after each of the three 5-day treatment periods. We did not determine whether recanalization of PVT improves the incidence of complications in patients with liver disease. Delgado et al. 10 reported that the number of patients developing liver-related events, after anticoagulation therapy, was lower in patients achieving recanalization of PVT, although the difference did not reach statistical significance. Therefore, further studies with similar clinical end-points are warranted.
In conclusion, this randomized, double-blind, controlled study shows that AT-III is safe and effective in liver disease patients with PVT, achieving complete and partial recanalization in 55.6% of the patients. To date, the PVT recanalization data in liver disease patients have been scarce, and the patients in these studies have lower concentration levels of AT-III. 8, 15 Therefore, AT-III should be considered an essential therapy for PVT in patients with liver disease.
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Table S1
Computed tomographic measurements in Figure 3 . 
